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Outcomes Following Melody Transcatheter Pulmonary Valve Implantation for Right 
Ventricular Outflow Tract Dysfunction in Repaired Congenital Heart Disease: First 
Reported Australian Single Centre Experience
Abstract
Background: Transcatheter pulmonary valve implantation (TPVI) with the Melody® 
transcatheter pulmonary valve (TPV) has demonstrated good haemodynamic and clinical 
outcomes in the treatment of right ventricular outflow tract (RVOT) conduit dysfunction in 
patients with repaired congenital heart disease CHD. We present the first Australian single 
centre experience of patients treated with Melody TPV.
Method: A prospective, observational registry was developed to monitor clinical and 
haemodynamic outcomes in patients with RVOT dysfunction treated with the Melody TPV 
(Medtronic Inc, Minneapolis, United States). 
Results: Seventeen patients underwent TPVI with Melody TPV at The Prince Charles 
Hospital between January 2009 and February 2016 with a median (range) age of 34 (R: 15–
60). Fifteen (88%) were NYHA Class 2 dyspnoea and 11 (59%) had corrected Tetralogy of 
Fallot. Indication for TPVI was stenosis in eight (47%), regurgitation in two (12%) and 
mixed dysfunction in seven (41%). Device implantation was successful in all patients. Peak 
RVOT gradient was significantly reduced and there was no significant regurgitation post 
procedure. There was one (6%) major procedural adverse event and two (12%) major adverse 
events at last recorded follow-up. There were no patient deaths. Follow-up cardiac magnetic 
resonance imaging revealed a significant reduction in indexed right ventricular end diastolic 
volume. 
Conclusion: This study confirms the safety and effectiveness of TPVI with Melody TPV for 
RVOT dysfunction in repaired CHD.
Key words: Cardiac catheterisation, Pulmonary valve implantation, Heart valve prosthesis, 
Conduit
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Introduction
Long-term durability of surgical intervention on the right ventricular outflow tract (RVOT) 
for congenital heart disease (CHD) is highly variable, with allograft or bioprosthetic valves 
becoming dysfunctional and requiring further intervention over time (1). Transcatheter 
pulmonary valve implantation (TPVI) with the Melody® transcatheter pulmonary valve 
(TPV) (Medtronic Inc, Minneapolis, United States) has demonstrated good haemodynamic 
and clinical outcomes in the treatment of RVOT conduit dysfunction in patients with repaired 
CHD (2, 3). Numerous trial and registry data have demonstrated reduced RVOT gradients, 
elimination of pulmonary regurgitation or stenosis and good clinical outcomes early after 
implantation (4-7). This report presents immediate and long-term clinical and haemodynamic 
outcomes after TPVI with the Melody TPV in patients with repaired CHD in a single centre 
as a first reported Australian experience. We aim to describe the procedural outcomes, to 
detail any complications, with early and late follow-up of this Australian cohort of TPVI 
recipients.
METHODS
Study Design
A prospective, observational registry was developed to monitor clinical and haemodynamic 
outcomes, procedural indications and complications, and long-term follow-up in patients with 
RVOT dysfunction treated with the Melody TPV up to last recorded follow-up. Prior to 
TPVI, all patient cases were presented at a multidisciplinary meeting and required consensus 
agreement from congenital cardiologists, interventional cardiologists, cardiothoracic surgeons 
with expertise in CHD, congenital radiologists and allied health staff. 
Inclusion Criteria
To be eligible for TPVI with the Melody TPV patients needed an original RVOT conduit 
and/or pulmonary artery diameter ≥16mm and ≤22mm. Patients needed to be either, a) 
symptomatic with dyspnoea, mean RVOT gradient >35mmHg and/or moderate pulmonary 
valve regurgitation, or b) NYHA class 1 with mean RVOT gradient ≥40mmHg and/or severe 
pulmonary valve regurgitation. Patients without contraindications underwent cardiovascular 
magnetic resonance imaging (CMR) to determine right ventricular end-diastolic volume 
indexed to body surface area (RVEDVi), right ventricular ejection fraction (RVEF) and to 
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quantitate pulmonary regurgitation prior to intervention. Coronary artery relationship to the 
RVOT conduit was assessed either via CMR, computed tomography coronary angiography 
(CTCA) or cardiac catheterisation. Patients were excluded from TPVI with the Melody TPV 
if they were pregnant, had active infection, psychosocial dysfunction precluding implantation 
and follow-up, or structural and anatomical malformations that prevented percutaneous 
access and/or device deployment. Patients with native (primary) RVOT dysfunction were 
excluded.
Procedure
Procedures were performed under general anaesthesia by a single operator with extensive 
experience in percutaneous structural intervention (DLW). All patients underwent right heart 
catheterisation and pulmonary angiography accessed via the right/left femoral vein. A 
Cournand catheter (Medtronic, Minneapolis, United States) with a stiff Meier wire (Boston 
Scientific, Massachusetts, United States) was used as a guide. Simultaneous RVOT balloon 
sizing and aortic root angiography was performed to rule out coronary artery compression in 
all patients. Dyna CT (CT scan using the cath lab C-arm) was used in the majority of patients 
to assess the best radiographic view and angle for deployment. All patients underwent pre-
stenting of the RVOT with either a covered CP stent (Numed, New York, United States) or 
an eV3 stent (eV3 Endovascular Inc, Minneapolis, United States). Post-dilation was 
performed with a Mullins-X balloon (BV Medical, Leicestershire, United Kingdom). An 
Ensemble Delivery system (Medtronic, Minneapolis, United States) was then used to deploy 
the Melody TPV under fluoroscopy or transoesophageal echocardiography guidance. Post 
procedural right heart catheterisation measurements were obtained to determine residual 
gradients across the valve and pulmonary angiography was performed to confirm Melody 
TPV competency.
Data Collection and Follow-Up
Procedural data along with baseline demographics was collected at the time of procedure. 
Successful device insertion was defined as deployment of single Melody TPV in the RVOT 
conduit with no significant regurgitation or gradient and no procedural mortality. Valve 
function was assessed post deployment by right heart catheterisation post pulmonary 
angiography, and/or transoesophageal echocardiography. Patients would have transthoracic 
echocardiogram the following day and be examined by the implanting cardiologist each day 
during their admission.
Page 5 of 20
Ac
ce
pte
d M
an
us
cri
pt
Patients were reviewed at 1, 6 and 12 months and annually thereafter. At each review, 
patients underwent routine electrocardiography, transthoracic echocardiography and 
completed a questionnaire to capture adverse events. Serial chest X-rays were performed 
annually to look for stent fractures. Adverse events were recorded retrospectively when 
follow-up was performed at other institutions. Major adverse events were defined as death, 
cardiovascular death, stroke/transient ischaemic attack, myocardial infarction or device 
malfunction (need for repeat procedure, failed deployment, significant residual stenosis, 
significant valvular or paravalvular regurgitation, strut/stent fracture, infection or 
embolisation). Major vascular complications were defined as those requiring 
interventional/surgical correction, blood transfusions or prolonged hospital stay. Major 
procedural adverse events were defined as any major adverse event that occurred during the 
procedure or within 24 hours after Melody TPV deployment. Minor adverse events were all 
adverse events that did not fall into an aforementioned group and did not cause significant 
harm. NYHA class and functional status were also recorded at each review.
Imaging
Pre-procedural echocardiographic evaluation was performed per American Society of 
Echocardiography guidelines including: RVOT sizing, 2D pulmonary valve imaging, 
continuous and pulsed wave Doppler analysis for pulmonary valve mean and peak gradients, 
right and left ventricular size and systolic function and colour flow mapping of the RVOT to 
assess valvular regurgitation. Intra-procedural imaging was performed with transoesophageal 
echocardiography using a matrix array transducer with 3D imaging capability (X7-2t, Philips 
Healthcare Andover, MA). Follow-up CMR was performed on a 1.5T system using steady 
state free precession cine imaging, and phase contrast flow quantitation in patients with no 
contraindications (pa emaker or defibrillator).
Statistical Analysis 
Descriptive data are presented as means ± standard deviation when normally distributed or as 
medians with range when abnormally distributed. Categorical variables are reported as 
frequencies and compared with Chi-Square (x2) statistic and continuous variables were 
compared with a two-tailed t-test. A p-value less than 0.05 was considered as significant. 
Statistical analyses were performed using GraphPad Prism version 5.0 (GraphPad, San 
Diego, United States).
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Ethics
Ethical permission for this study was obtained through The Prince Charles Hospital Human 
Research Ethics Committee (HREC/16/QPCH/207).
RESULTS
Patient and Procedural Characteristics
Seventeen patients with a median age of 34 (R: 15–60) years underwent TPVI with Melody 
TPV at The Prince Charles Hospital between January 2009 and February 2016 and were 
included in the analysis. Baseline characteristics are summarised in Table 1.
All patients had access via the right or left femoral vein with an Ensemble delivery system, 
pre-dilatation of the stenosis, and deployment of a covered stent in the RVOT conduit. 
Median procedure time was 106 minutes. Procedural data are described in Table 2. 
Procedural and Haemodynamic Outcome 
A Melody TPV was successfully deployed in all patients. Invasive haemodynamic 
measurements showed a significant improvement in RVOT peak gradient and right 
ventricular systolic pressure (RVSP) post TPVI (41mmHg vs 13mmHg, p<0.001 and 
69mmHg vs 43mmHg, p<0.001). There was no significant residual pulmonary regurgitation 
in any patient post procedure.
Complications
There was one major procedural adverse event; this involved an RVOT conduit tear resulting 
in a small loculated pericardial haemorrhage adjacent to the Melody TPV and pulmonary 
haemorrhage with air leak into the pleural and mediastinal space that was either a 
complication of the TOE probe, intubation or pulmonary artery catheter.  The event occurred 
in a 27-year-old male with a stenosed RVOT homograft conduit created to correct congenital 
pulmonary atresia 20 years prior. A 20 mm Ensemble delivery system was used with right 
femoral vein access using a 14 French sheath. A 14 French Mullins sheath was advanced to 
the pulmonary conduit stenosis and an 18 mm x 4.5 cm Cristal balloon was inflated across 
the valve with a simultaneous aortogram showing satisfactory coronary anatomy. An 18 mm 
CP stent was deployed with a 30 mm x18 mm BIB. A 20 mm Ensemble delivery system was 
used to deploy an 18 mm Melody TPV. No significant pulmonary stenosis or regurgitation 
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was noted on intraprocedural transoesophageal echocardiography. No dye hang-up or 
contrast extravasation was noted on pulmonary angiography post deployment to suggest 
conduit rupture or peripheral arterial perforation. Furthermore, there was no major 
haemodynamic compromise during or immediately after the procedure.  The following day 
the patient became hypoxic. Chest CT was performed which demonstrated the 
aforementioned findings of pneumo-mediastinum. The patient was treated conservatively 
without any surgical intervention and under close observation in the Coronary Care Unit. 
Interval chest CT after 48 hours demonstrated reduction is size of pneumomediastinum with 
the small loculated pericardial haemorrhage stable in size. He remained haemodynamically 
stable, oxygenation improved and he was discharged day 6 post procedure, and was well at 
clinical follow-up.
There were four minor procedural adverse events. The first was a residual stenosis of 21
mmHg across the RVOT conduit at the end of the procedure in a 28-year-old female with 
corrected Tetralogy of Fallot and RVOT conduit stenosis; given the predefined endpoint of 
procedural success being absence of a significant residual gradient, this therefore was defined 
as an adverse event. An 18 mm Ensemble delivery system was used via the right femoral vein 
within an 8Fr 24 cm long arrow sheath. The length of the stenotic conduit was pre-
procedurally sized at 30 mm using CT imaging and pulmonary angiography. A 39 mm CP 
stent was mounted on a 22 mm x 5.0 cm BIB and deployed through a 12 Fr Mullins sheath. 
The delivery system was used to deploy an 18 mm Melody TPV and the valve post dilated 
with a 22 x 40 mm Mullins-X balloon (four inflations at 12 atmospheres). A residual 
pulmonary peak gradient of 21 mm was noted on post procedural right heart catheter 
measurements.
Other minor procedural events included: failure of the RVOT stent to be deployed, this was 
retrieved with a ‘gooseneck’ snare and a Melody TPV successfully implanted thereafter. In 
another patient the valve was unable to be uncovered due to rupture of the plastic delivery 
system. The delivery system was then removed, the Melody TPV reloaded and successfully 
implanted. Finally, one patient had a burst balloon during implantation, but the device was 
successfully implanted with no clinical complications. Procedural outcomes are described in 
Table 3.
Page 8 of 20
Ac
ce
pte
d M
an
us
cri
pt
Clinical Outcome
Mean follow-up was 34.9 months (R: 3.1–69.6 months). All patients were alive at last 
recorded follow-up. NYHA class improved or remained stable in all patients at last recorded 
follow-up. NYHA was unknown in three patients at last recorded follow-up. One patient 
remained NYHA class 1 having had TPVI for elevated RVOT gradients only. There was one 
case of minor Melody TPV stent fracture detected at last recorded follow-up on routine chest 
X-ray. This did not result in any device malfunction or any clinical adverse event. 
There were two cases of late device malfunction at last recorded follow-up. Both events 
occurred in the same patient, a 21-year-old male with repaired Tetralogy of Fallot, previous 
splenectomy and Melody TPV for mixed stenosis and regurgitation through an RVOT 
conduit. The first event was Streptococcus mitis bacteraemia at 12 months post index 
procedure. Septic screening tests along with transthoracic and transoesophageal echo could 
not identify an infective source of bacteraemia. It was presumed to be Melody TPV infective 
endocarditis and treated with six weeks of intravenous penicillin. The patient experienced no 
further recurrence of infection since treatment. 
Melody TPV stenosis occurred in the same patient 18-months post index procedure. 
Transthoracic and transoesophageal echocardiogram indicated thrombotic pannus as the 
likely cause with transthoracic echocardiogram demonstrating a mean gradient of 54 mmHg 
through the Melody TPV. Therapeutic anticoagulation with warfarin was initiated and mean 
gradient through the Melody TPV reduced to 37 mmHg. 
Other notable events not directly related to TPVI included out of hospital cardiac arrest in a 
27-year-old male three years after index procedure. The patient had initially presented with 
pulmonary regurgitation after Rastelli with double switch operation. At the time of the arrest 
his sub-pulmonic left ventricle was normal in size and function and the systemic right 
ventricle was severely dilated with mild systolic dysfunction. Computed tomography 
coronary angiography revealed no significant coronary disease. It was treated as primary 
ventricular fibrillation arrest secondary to systemic right ventricular dysfunction and a 
cardiac defibrillator was implanted with great difficulty due to his anatomy. He subsequently 
developed pocket site infection of the defibrillator which was treated with a short course of 
intravenous antibiotics and resolved without any further intervention required. 
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Imaging Outcomes
Cardiac magnetic resonance data revealed significant improvement in right ventricular 
remodelling as evidenced by reduction in RVEDVi (122mls/m2 vs 108mls/m2, p<0.001) with 
no significant change in RVEF (43% vs 45%, p=0.42). Echocardiographic data demonstrated 
improvement in RVOT mean pressure gradient post procedurally and persisted out to last 
recorded follow-up. Serial transthoracic echocardiography revealed significant reduction in 
mean RVOT gradient and RVSP pre-procedurally compared with last follow-up (57 mmHg 
vs 27 mmHg, p<0.001 and 60 mmHg vs 33 mmHg, p<0.001). There was no significant 
change in left ventricular systolic function pre procedurally versus last recorded follow-up 
(Figure 1).  
Discussion
This study is the first reported Australian experience of TPVI with Melody TPV for RVOT 
dysfunction in repaired CHD and confirms its safety and effectiveness in this context. In this 
report, we have detailed the indications, the procedural complications, and early- and late-
follow-up with clinical, imaging, and haemodynamic outcomes. 
These data are consistent with other reported studies (4, 5, 7-9).  The registry of the Italian 
Society of Paediatric Cardiology included 63 patients who underwent TPVI with Melody 
TPV (5). Median age was 24 years (R: 11–65) with a median of three previous surgeries 
(R:1–5) and mixed aetiology of repaired CHD. Successful device insertion occurred in 61 
(97%), mean procedure time was 170 minutes (R:85–360), pre-stenting was performed in 53 
(85%). Procedural complications occurred in 9 (14%) including one death. This registry had 
higher rates of procedural complications compared to ours and is likely due to the higher risk 
patients in which TPVI was attempted. Eight (13%) had associated procedures including 
ventricular septal defect closure, aorto-pulmonary artery embolisation and pulmonary artery 
stent implantation versus none in our registry. There was one early mortality which occurred 
in the context of TPVI performed on compassionate grounds in a patient with septic shock 
and four previous cardiac surgeries. In contrast to our registry, all patients were clinically 
stable and performed as elective procedures. Twenty-three (37%) of the patients from the 
Italian registry were either NYHA III or IV class dyspnoea prior to TPVI as compared to one 
(6%) in our registry.
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A second registry based in France included 64 patients who underwent TPVI for RVOT 
dysfunction in repaired CHD (4). Median age was 21.4 years (R:10.5–77.3), median 
procedure time was 92 minutes (R: 25–250). Sixty-two (96.9%) had access via femoral vein, 
62 (96.9%) had pre-stenting and no patient was NYHA IV.  Procedural success occurred in 
all patients and there were no major complications. Minor procedural complications occurred 
in 11 (17.2%) patients and included: confined tear in RVOT conduit treated with covered 
stent, minor bleeding from orotracheal tube and access site pseudoaneurysm. In comparison, 
our registry had one likely confined tear in the RVOT conduit, the risk of which was 
minimised with routine pre-stenting before deployment of Melody TPV. Indeed Melody TPV 
itself has been used to correct RVOT conduit rupture following balloon angioplasty (10).
In the French registry three patients died in the follow-up period; two from infective 
endocarditis and one from heart failure. The two cases of infective endocarditis occurred at 
2.6 and 28.3 months after TPVI and involved RVOT conduit obstruction from valve 
vegetation. Late infective endocarditis with Melody TPV has been reported in other studies 
with the most common organisms being Staphylococcus or Streptococcus species (5, 7, 11). 
Abrupt aspirin discontinuation and additional unprotected invasive procedures have been 
described as independent predictors of Melody TPV infective endocarditis (12). Our registry 
had one possible case of device infection. The event must be considered in the context of 
baseline immunocompromise with the patient having previously had a splenectomy. 
Furthermore, only one blood culture was positive with several subsequent negative blood 
cultures prior to the initiation of antibiotics makes the diagnosis of Melody TPV presumptive. 
Nevertheless there remains a long-term risk of infective endocarditis, as for any prosthetic 
valve.
The patient who died from heart failure in this French registry presented 23.7 months after 
TPVI and had the index procedure in the setting of advanced heart failure with severe 
biventricular dysfunction. By comparison, all except one of our patients had normal left 
ventricular ejection fraction at baseline and likely contributes to the low incidence of heart 
failure and death in the follow-up period. 
Stent fracture for Melody TPV has a reported prevalence of 33±4% at one year after TPVI 
when assessed with routine chest radiography and multiplane fluoroscopy and need for 
RVOT reintervention was 14±4 at two years in the early studies (13). Transcatheter 
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pulmonary valve compression and apposition to the anterior chest wall were associated with 
shorter freedom from stent fracture and need for RVOT reintervention (13). Our registry had 
lower rates of stent fracture than other early registries which was likely due to routine pre-
stenting prior to Melody TPV deployment. Pre-stenting has demonstrated significant 
reductions in percutaneous pulmonary valve stent fractures as compared to percutaneous 
pulmonary valve implantation alone and has become standard in the modern era (HR 0.35, 
95% CI 0.14–0.87, p=0.024)(13). By providing a defined conduit for placement of Melody 
TPV and absorbing radial load, pre-stenting appears to be a safe and effective means of 
improving outcome in TPVI. A limitation from this study was that no routine CT or 
fluoroscopic investigations were performed, other than chest X-ray, to assess for stent strut 
fracture. This may have led to an under-reporting of stent fracture in the follow-up period. 
Patients with abnormal coronary anatomy tend to be at a non-statistically significantly higher 
risk of coronary artery compression due to aberrant arterial courses running close to the 
conduit, compared to those with normal coronary arterial anatomy (14). A US registry looked 
at the incidence and predictors of coronary artery compression with Melody TPV and found 
5% of patients had evidence of coronary artery compression during simultaneous RVOT and 
coronary angiography and 71% of this subset had abnormal coronary anatomy. These patients 
did not undergo TPVI. Patients with a history of Tetralogy of Fallot and transposition of the 
great arteries were at increased risk of coronary artery compression (15). Coronary artery 
compression after Melody TPVI has been described up to three months post TPVI (16). In 
our experience, cross-injection via selective engagement of the aberrant coronary artery 
during balloon inflation allowed careful intra-procedural evaluation of compression, and in 
all cases allowed safe delivery of the Melody TPV without complication. Pre-procedural 
planning with CTCA or MRI was also important in preventing coronary artery compression.
DynaCT (CT scan performed using the hybrid lab C-arm) was employed to image the RVOT 
conduit and optimise fluoroscopic implant angles. This technique has been used in imaging 
the aortic root and the ilio femoral system in transcatheter aortic valve replacement with 
proven benefit for successful valve deployment and access site complications (17). Our 
experience suggests that it may also be of benefit in TPVR. Comparison between major 
Melody TPV registries and this study are described in Table 4.
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Cost analysis of percutaneous pulmonary valve replacement has been performed through 
comparison to standard surgical conduit replacement. Cost of Melody TPV was $30,500 USD 
higher than surgical conduit cost of $8,700 USD, however the total procedural costs were 
nearly identical at just less than $50,000 USD. Over the subsequent years, given the need for 
repeat re-intervention, surgical conduits resulted in modest cost savings (18). The anatomic 
variability of the RVOT conduit and its mechanical variability in the chest still need to be 
addressed in the design and development process of percutaneous valve intervention (19). 
These benefits must be taken in the context of improving percutaneous technology techniques 
which will hopefully result in reduced long-term costs.
Limitations
The lack of standardised single centre follow-up at the treating institution was a limitation of 
this study, which may have impaired the accuracy of long-term outcome data. This was 
largely unavoidable. Due to the highly specialised nature of the procedure, a number of 
patients in this series were referred from interstate or from distances over 1000 km. Follow-
up within the first year was typically performed at our hospital, however after that most 
patients chose to have annual follow-up with a local cardiology service and/or via telehealth 
link. As such serial data parameters such as echocardiograms and ECG were not 
standardised. This issue was addressed in best part through phone calls performed prior to 
data collection for this study to ensure no adverse events had been missed.
Conclusion
This study presents the first reported Australian longitudinal data using the Melody TPV and 
confirms the safety and effectiveness of TPVI with Melody TPV for RVOT dysfunction in 
repaired CHD. Multidisciplinary input, careful pre-procedural imaging to identify suitability 
as well as variant coronary anatomy, and intra-procedural imaging with angiography, 
fluoroscopy +/- transoesophageal echocardiography allowed for minimal adverse events with 
excellent long-term outcomes when performed electively in appropriately selected patients 
for treatment of RVOT dysfunction.
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Table 1 Baseline Patient and Conduit Characteristics
Patient Data
Age (years) 34 (R: 15-60)
Height (m) 1.65±0.09
Weight (kg) 74.9±17.0
Body Mass Index (kg/m2) 27.4±6.2
Male 9 (53)
NYHA Class II 15 (88)
CHD 17 (100)
Tetralogy of Fallot 11 (59)
Truncus arteriosus 1 (6)
Ross procedure 3 (17)
Rastelli procedure 1 (6)
Pulmonary atresia 2 (12)
Variant coronary artery anatomy 2 (12)
Previous number of cardiac surgeries 3 (R: 1-4)
Echocardiographic LVEF % 61±9
Cardiac MRI Data
Mean RVEF % 43±12
Mean RVEDVi (mL/m2) 122±54
Indication
Stenosis 8 (47)
Regurgitation 2 (12)
Mixed Stenosis and Regurgitation 7 (41)
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Table 2 Procedural Characteristics
Femoral Approach 17 (100)
General anaesthesia 17 (100)
Median sheath size (Fr) 22 (R: 14-22)
Ensemble delivery system 17 (100)
Median conduit stenosis diameter (mm) 13.9 (R: 10.8-22 
Predilation 17 (100)
Median Melody TPV diameter (mm) 21 (R:18-22)
Associated procedure performed 0 (0)
Pre-stenting 17 (100)
Median procedure time (minutes) 106 (R:86-173)
Median contrast used (mls) 270 (R: 120-440)
Dose Area Product (uGy/m2) 24330 (R: 3630-44629)
Fluroscopy time (minutes) 30 (R:22-51)
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Table 3 Procedural and Last Recorded Follow-up Haemodynamic and Clinical Outcomes
Pre-procedure Post-procedure Last recorded 
follow-up
P-value
Successful device insertion N/A 17 (100) N/A
Invasive haemodynamics
RVSP (mmHg) 69±25 43±14 N/A <0.001
RVOT peak gradient (mmHg) 41±24 13±8 N/A <0.001
Echocardiographic data
Pulmonary Regurgitation Grade
0 7 17 15 <0.001
1 4 0 1
2 3 0 1
3 2 0 0
4 1 0 0
RVOT peak pressure gradient 
(mmHg)
57±16 27±10 27±15 <0.001
RVOT mean pressure gradient 
(mmHg)
35±10 15±6 15±9 <0.001
RVSP (mmHg) 60±18 46±11 33±11 <0.001
LVEF (%) 59±8 61±6 57±6 0.28
Cardiac MRI Data
RVEF (%) 43±12 N/A 45±10 0.42
RVEDVi (mL/m2) 122±54 N/A 108±32 <0.001
Clinical NYHA Class
I 1 N/A 11 P<0.001
II 15 N/A 2
III 1 N/A 0
IV 0 N/A 0
Unknown 0 N/A 3
Major Adverse Events
Death N/A 0 0
Myocardial Infarction N/A 0 0
Stroke/TIA N/A 0 0
Major vascular N/A 1 
(pulmonary/RVOT)
0
Device malfunction N/A 0 2
Minor Adverse Events N/A 4 N/A
Stent Fracture N/A 0 1
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Table 4 Comparative Registry Outcome Data
Study Author Year Number Age 
(central 
tendency)
Follow-
up 
(months)
Pre-
stenting 
N (%)
Pre -
Peak 
RVOT 
gradient 
(mmHg)
Post-
Peak 
RVOT 
gradient 
(mmHg)
Procedural 
complication 
N (%)
Procedural 
Death N 
(%)
Stent 
fracture 
N (%)
Device 
infection
N (%)
Device 
malfunction 
requiring 
re-
intervention 
N (%)
Death 
N 
(%)
McElhinney(9) 2010 136 19 24 49 (35) 37 12 8 (6) 1 (0.7) 25 (18) 0 (0) 16 (12) 1(0.7)
Eicken (7) 2011 102 22 12 97 (95) 37 14 1 (1) 1 (1) 5 (5) 1 (1) 8 (8) 1 (1)
Butera (5) 2013 63 24 30 54 (85) 45 10 7 (11) 1 (2) 2 (3) 2 (3) 2 (3) 3 (5)
Vezmar (20) 2010 28 15 24 7 (25) 36 12 1 (3) 0 (0) 3 (11) 0 (0) 6 (20) 0 (0)
Fraisse (4) 2014 64 21 48 62 (97) 50 14 5 (8) 0 (0) 0 (0) 1 (2) 3 (5) 3 (5)
Zahn (6) 2009 34 19 6 0 (0) 37 17 3 (9) 0 (0) 8 (24) 0 (0) 3 (9) 0 (0)
Cheatham (3) 2015 171 19 53 62 (36) - - 1 (0.5) 1 (0.5) 22 (13) 3 (2) 41 (24) 4 (2)
Current Study 2016 17 34 35 17(100) 41 13 1 (6) 0 (0) 1 (6) 1 (6) 0 (0) 0 (0)
Page 20 of 20
Ac
ce
pte
d M
an
us
cri
pt
Figure 1. Haemodynamic and functional outcome as assessed by TTE and CMRI
